Gouty Arthritis (Gout) Pipeline Review, H1 2018 - Assessment by Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Gouty Arthritis (Gout) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide 'Gouty Arthritis (Gout) - Pipeline Review, H1 2018', provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 11, 1, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Companies Mentioned

  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Horizon Pharma Plc
  • Immune Response BioPharma Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Opsona Therapeutics Ltd
  • Polaris Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • Teijin Pharma Ltd
  • Wellstat Therapeutics Corp
  • XL-protein GmbH

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Gouty Arthritis (Gout) - Overview
  4. Gouty Arthritis (Gout) - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Gouty Arthritis (Gout) - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development

For more information about this report visit https://www.researchandmarkets.com/research/kc2dph/gouty_arthritis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs